ANGO stock sentiment todayAngioDynamics, Inc.
Sentiment verdict
Gossip first, financials second — NEUTRAL at 65% confidence.
Last updated · cached analysis, refreshes periodically
ANGO
AngioDynamics, Inc.A transitional med-tech play pivoting from legacy hardware to high-margin MedTech, currently hampered by lack of profitability.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for ANGO. Not financial advice.
Price · last 12 months
Gossip
The narrative centers on a strategic 'portfolio optimization' following the sale of its PICC and Midline businesses to BD. The market is cautiously watching the ramp-up of AlphaVac and Auryon while waiting for the company to prove it can reach adjusted EBITDA profitability after years of restructuring.
- ·FDA clearance momentum for AlphaVac in PE (Pulmonary Embolism)
- ·Divestiture of lower-margin legacy assets
- ·Shift toward 'MedTech' high-growth segments (NanoKnife, Auryon)
Financial
Fundamentals are in a state of flux; while top-line growth in key MedTech segments is impressive (double digits), the company remains net-loss generating on a GAAP basis. The balance sheet was recently bolstered by divestiture proceeds, providing a runway to reach cash-flow break-even.
- ·Negative trailing P/E due to lack of GAAP net income
- ·Gross margins improving toward 50-55% target range
- ·Manageable debt-to-equity following recent asset sales
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders sold a net $344K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Execution risk in highly competitive mechanical thrombectomy market
- ·Dependence on narrow high-growth product lines (Auryon/AlphaVac)
- ·History of dilutive capital raises and missing profitability targets
Peer temperature
How direct competitors stack up against ANGO right now.
- HOTPENPenumbra, Inc.
HOTTER — Dominant market share in thrombectomy with superior revenue scale and consistent GAAP profitability.
See full analysis → - NEUTRALTFXTeleflex Inc.
COLDER GROWTH — Offers much higher stability and dividends but lacks the high-upside 'pure play' MedTech growth narrative of ANGO.
See full analysis → - HOTSWAVShockwave Medical (Acquired by JNJ)
HOTTER — Though acquired, it represents the high-valuation, high-margin intravascular lithotripsy success that ANGO aspires to replicate.
See full analysis →
- ANGO+8.3%
- PEN+0.5%
- TFX+3.7%
- SWAV—
Analyst price target
Consensus average of 4 analysts · median 20.00
Source: StockAnalysis.com · updated 2026-08-12
AI-generated analysis for informational purposes only. Not financial advice.